Billion-Dollar Portfolio Manager from Jazz Pharma Takes Helm at Akari Therapeutics - Stock Titan
2025-03-20 • Google News
Akari Therapeutics PLC (AKTX)
US$ 1.2222%
Price Chart
Key Statistics
Market Cap
$ 40.72M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
148.83K
52W High
$ 4.40
52W Low
$ 0.85
Dividend Yield
0.00%
Beta
0.29
Technicals
50-Day MA
1.1761
200-Day MA
2.0164
52 Week High
4.4
52 Week Low
0.85
About AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a secon.
Employees
8
Headquarters
Boston, MA
CEO
Mr. Abizer Gaslightwala
Latest News
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology - GlobeNewswire
1 weeks ago • Google News
Akari Therapeutics (AKTX) Introduces New CEO in Corporate Update Video | AKTX Stock News - GuruFocus
3 weeks ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg